Chromatin states define tumour-specific T cell dysfunction and reprogramming

被引:641
|
作者
Philip, Mary [1 ,3 ]
Fairchild, Lauren [2 ]
Sun, Liping [4 ]
Horste, Ellen L. [1 ]
Amara, Steven C. [1 ]
Shakiba, Mojdeh [1 ,5 ]
Scott, Andrew C. . [1 ,5 ]
Viale, Agnes [4 ]
Lauer, Peter [6 ]
Erghoub, Taha M. [5 ,7 ]
Hellmann, Matthew D. [5 ,8 ]
Wolchok, Jedd D. [5 ,7 ,9 ]
Leslie, Christina S. [2 ]
Schietinger, Andrea [1 ,5 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Computat Biol Program, New York, NY 10065 USA
[3] Weill Cornell Med Coll, Triinst Training Program Computat Biol & Med, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Ctr Mol Oncol, Integrated Genom Operat, New York, NY 10065 USA
[5] Cornell Univ, Weill Cornell Med Coll, New York, NY 10065 USA
[6] Aduro Biotech Inc, Berkeley, CA 94720 USA
[7] Mem Sloan Kettering Canc Ctr, Melanoma & Immunotherapeut Serv, New York, NY 10065 USA
[8] Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv, New York, NY 10065 USA
[9] Mem Sloan Kettering Canc Ctr, Ludwig Ctr Canc Immunotherapy, New York, NY 10065 USA
关键词
DIFFERENTIAL EXPRESSION; TRANSCRIPTIONAL CONTROL; CANCER; EFFECTOR; LANDSCAPE; PROTEINS; BLOCKADE; ANTIGEN; BIAS;
D O I
10.1038/nature22367
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Tumour-specific CD8 T cells in solid tumours are dysfunctional, allowing tumours to progress. The epigenetic regulation of T cell dysfunction and therapeutic reprogrammability (for example, to immune checkpoint blockade) is not well understood. Here we show that T cells in mouse tumours differentiate through two discrete chromatin states: a plastic dysfunctional state from which T cells can be rescued, and a fixed dysfunctional state in which the cells are resistant to reprogramming. We identified surface markers associated with each chromatin state that distinguished reprogrammable from non-reprogrammable PD1(hi) dysfunctional T cells within heterogeneous T cell populations from tumours in mice; these surface markers were also expressed on human PD1(hi) tumour-infiltrating CD8 T cells. Our study has important implications for cancer immunotherapy as we define key transcription factors and epigenetic programs underlying T cell dysfunction and surface markers that predict therapeutic reprogrammability.
引用
收藏
页码:452 / +
页数:21
相关论文
共 50 条
  • [21] Disabling adenosine-mediated suppression of tumour-specific cytotoxic T lymphocyte function
    Basingab, F. S. H.
    Al-Yafei, Z.
    Koundouros, N.
    Morgan, D.
    IMMUNOLOGY, 2014, 143 : 60 - 60
  • [22] Autologous tumour-specific cytotoxic T-lymphocytes in osteosarcoma patients: a preclinical model
    Muraro, M.
    Signorino, E.
    Castiglia, S.
    Sangiolo, D.
    Mereuta, M.
    Saglio, F.
    Ferrero, I.
    Aglietta, M.
    Fagioli, F.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S381 - S382
  • [23] Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer
    J M Coulson
    J Stanley
    P J Woll
    British Journal of Cancer, 1999, 80 : 1935 - 1944
  • [24] Comparison of Tumour-Specific Phenotypes in Human Primary and Expandable Pancreatic Cancer Cell Lines
    Guo, Feng
    Kan, Kejia
    Rueckert, Felix
    Rueckert, Wolfgang
    Li, Lin
    Eberhard, Johannes
    May, Tobias
    Sticht, Carsten
    Dirks, Wilhelm G.
    Reissfelder, Christoph
    Pallavi, Prama
    Keese, Michael
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [25] Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens
    Wolf, Melissa M.
    Rathmell, W. Kimryn
    de Cubas, Aguirre A.
    NATURE REVIEWS NEPHROLOGY, 2023, 19 (07) : 440 - 450
  • [26] Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer
    Coulson, JM
    Stanley, J
    Woll, PJ
    BRITISH JOURNAL OF CANCER, 1999, 80 (12) : 1935 - 1944
  • [27] Generation of tumour-specific cytotoxic T-lymphocytes from peripheral blood of colorectal cancer patients for adoptive t-cell transfer
    Corluccio, S.
    Delbue, S.
    Ferrante, P.
    Bregni, M.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S33 - S33
  • [28] Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens
    Melissa M. Wolf
    W. Kimryn Rathmell
    Aguirre A. de Cubas
    Nature Reviews Nephrology, 2023, 19 : 440 - 450
  • [29] Detection of Merkel cell polyomavirus with a tumour-specific signature in non-small cell lung cancer
    Hashida, Y.
    Imajoh, M.
    Nemoto, Y.
    Kamioka, M.
    Taniguchi, A.
    Taguchi, T.
    Kume, M.
    Orihashi, K.
    Daibata, M.
    BRITISH JOURNAL OF CANCER, 2013, 108 (03) : 629 - 637
  • [30] pDCs efficiently process synthetic long peptides to induce functional virus- and tumour-specific T-cell responses
    Aspord, Caroline
    Leloup, Claire
    Reche, Sabine
    Plumas, Joel
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2014, 44 (10) : 2880 - 2892